Susek, Katharina H.
Schwietzer, Ysabel A.
Karvouni, Maria
Gilljam, Mari
Keszei, Marton
Hussain, Alamdar
Lund, Johan
Kashif, Muhammad
Lundqvist, Andreas
Ljunggren, Hans-Gustaf
Nahi, Hareth
Wagner, Arnika K.
Alici, Evren
Funding for this research was provided by:
VINNOVA (2019-00056, 2019-00056, 2019-00056, 2019-00056, 2019-00056, 2019-00056, 2019-00056, 2019-00056, 2019-00056, 2019-00056, 2019-00056, 2019-00056, 2019-00056)
International Myeloma Society
Radiumhemmets Forskningsfonder (191063)
Castenbäcks Stiftelse för cancer research
Karolinska Institute
Article History
Received: 11 April 2022
Accepted: 25 October 2022
First Online: 10 November 2022
Declarations
:
: HN is employed by Genmab and a share holder of Genmab. EA, HG and AB are consultants for Vycellix. EA and HG are shareholders of Vycellix. AKW is consultant and shareholder of VyGenBio. A patent application has been submitted, covering this work (US Provisional application no 63286205).
: Ethical permits were granted by the Swedish Ethical Review board (Etikprövningsmyndighet) for work with patient derived PBMCs and bone marrow samples (Permit Numbers: 2019-04973 and 2020-02119).
: All authors declare their consent for publication.